Colin Bristow
Stock Analyst at UBS
(1.74)
# 3,361
Out of 5,154 analysts
105
Total ratings
40.32%
Success rate
-1.63%
Average return
Main Sectors:
Stocks Rated by Colin Bristow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENGN enGene Holdings | Maintains: Neutral | $4 → $10 | $8.68 | +15.21% | 3 | Nov 12, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $553 → $546 | $456.69 | +19.56% | 16 | Nov 7, 2025 | |
| GILD Gilead Sciences | Maintains: Neutral | $108 → $112 | $143.93 | -22.18% | 4 | Aug 8, 2025 | |
| PTCT PTC Therapeutics | Maintains: Buy | $71 → $80 | $62.82 | +27.35% | 4 | Jul 29, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $12 → $5 | $4.41 | +13.38% | 3 | Jun 17, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Buy | $1.2 → $1 | $2.21 | -54.75% | 6 | May 21, 2025 | |
| IMVT Immunovant | Downgrades: Neutral | $38 → $17 | $26.66 | -36.23% | 6 | Apr 22, 2025 | |
| AMGN Amgen | Maintains: Neutral | $315 → $319 | $369.53 | -13.67% | 9 | Apr 14, 2025 | |
| ABOS Acumen Pharmaceuticals | Maintains: Buy | $6 → $4 | $3.31 | +20.85% | 4 | Mar 28, 2025 | |
| PFE Pfizer | Maintains: Neutral | $29 → $28 | $27.05 | +3.51% | 13 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $120 | $115.79 | +3.64% | 7 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $234 → $202 | $184.87 | +9.27% | 10 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $56 → $16 | $1.48 | +981.08% | 5 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,090 → $1,099 | $759.86 | +44.63% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $164 → $167 | $16.71 | +899.40% | 5 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $428 → $420 | $990.33 | -57.59% | 1 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $2 | $11.54 | -82.67% | 2 | Dec 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $2.30 | +682.61% | 1 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $154 → $146 | $230.11 | -36.55% | 2 | Aug 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $75 | $60.29 | +24.40% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $64 → $26 | $3.04 | +755.26% | 1 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $4.94 | +82.19% | 1 | Aug 23, 2021 |
enGene Holdings
Nov 12, 2025
Maintains: Neutral
Price Target: $4 → $10
Current: $8.68
Upside: +15.21%
Vertex Pharmaceuticals
Nov 7, 2025
Maintains: Buy
Price Target: $553 → $546
Current: $456.69
Upside: +19.56%
Gilead Sciences
Aug 8, 2025
Maintains: Neutral
Price Target: $108 → $112
Current: $143.93
Upside: -22.18%
PTC Therapeutics
Jul 29, 2025
Maintains: Buy
Price Target: $71 → $80
Current: $62.82
Upside: +27.35%
Rocket Pharmaceuticals
Jun 17, 2025
Maintains: Buy
Price Target: $12 → $5
Current: $4.41
Upside: +13.38%
ALX Oncology Holdings
May 21, 2025
Maintains: Buy
Price Target: $1.2 → $1
Current: $2.21
Upside: -54.75%
Immunovant
Apr 22, 2025
Downgrades: Neutral
Price Target: $38 → $17
Current: $26.66
Upside: -36.23%
Amgen
Apr 14, 2025
Maintains: Neutral
Price Target: $315 → $319
Current: $369.53
Upside: -13.67%
Acumen Pharmaceuticals
Mar 28, 2025
Maintains: Buy
Price Target: $6 → $4
Current: $3.31
Upside: +20.85%
Pfizer
Feb 5, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $27.05
Upside: +3.51%
Jan 8, 2025
Maintains: Buy
Price Target: $125 → $120
Current: $115.79
Upside: +3.64%
Oct 3, 2024
Maintains: Neutral
Price Target: $234 → $202
Current: $184.87
Upside: +9.27%
Aug 9, 2024
Maintains: Neutral
Price Target: $56 → $16
Current: $1.48
Upside: +981.08%
Apr 17, 2024
Maintains: Buy
Price Target: $1,090 → $1,099
Current: $759.86
Upside: +44.63%
Mar 1, 2024
Maintains: Buy
Price Target: $164 → $167
Current: $16.71
Upside: +899.40%
Dec 15, 2022
Maintains: Buy
Price Target: $428 → $420
Current: $990.33
Upside: -57.59%
Dec 8, 2022
Downgrades: Neutral
Price Target: $12 → $2
Current: $11.54
Upside: -82.67%
Oct 18, 2022
Initiates: Buy
Price Target: $18
Current: $2.30
Upside: +682.61%
Aug 1, 2022
Maintains: Neutral
Price Target: $154 → $146
Current: $230.11
Upside: -36.55%
Jul 28, 2022
Maintains: Neutral
Price Target: $73 → $75
Current: $60.29
Upside: +24.40%
Apr 18, 2022
Maintains: Buy
Price Target: $64 → $26
Current: $3.04
Upside: +755.26%
Aug 23, 2021
Initiates: Buy
Price Target: $9
Current: $4.94
Upside: +82.19%